Update on apelin peptides as putative targets for cardiovascular drug discovery

Expert Opinion on Drug Discovery

Volumn 6, Issue 6, 2011, Pages 633-644

  Charles, Christopher J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

apelin; APJ; arterial pressure; cardiac output; cardiovascular disease; heart failure; peptide; vasoactive hormone

Indexed keywords

ADIPOCYTOKINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; APELIN 13; APELIN 36; ARGIPRESSIN; GALACTIN 3; MESSENGER RNA; MYOSIN LIGHT CHAIN; PROLACTIN; REACTIVE OXYGEN METABOLITE; SODIUM PROTON EXCHANGE PROTEIN; TELMISARTAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BLOOD VOLUME; BONE MARROW TRANSPLANTATION; CARBOXY TERMINAL SEQUENCE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG RESEARCH; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOREARM BLOOD FLOW; GENE EXPRESSION REGULATION; GENE INACTIVATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE INJURY; HEART OUTPUT; HEART PROTECTION; HEMODYNAMICS; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; LIQUID CHROMATOGRAPHY; LUNG DISEASE; MAMMARY ARTERY; MICROARRAY ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEQUENCE HOMOLOGY; SYSTOLIC DYSFUNCTION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; VASODILATATION;

EID: 79957565011     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.571251     Document Type: Review

References (89)

1. O'Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993;136:355-60 Discovery of the APJ receptor.
2. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;6:471-6 Discovery of apelin, the endogenous ligand for APJ, lowers blood pressure in rats.
3. Charles CJ. The apelin peptides as putative targets in cardiovascular drug discovery and development. Exert Opin Drug Discov 2008;3:51-64 (Pubitemid 351188344)
4. Habata Y, Fuji R, Hosoya M, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrums. Biochim Biophys Acta 1999;1452:25-35 (Pubitemid 29486739)
5. Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001;1538:162-71 (Pubitemid 32402239)
6. Tatemoto K, Takayama K, Zou M, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Reg Peptides 2001;99:87-92 The first report to suggest apelin lowers blood pressure via a NO mechanism.
7. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-43 (Pubitemid 34952556)
8. El Messari S, Iturrioz X, Fassot C, et al. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J Neurochem 2004;90:1290-301 (Pubitemid 39223633)
9. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74:34-41 (Pubitemid 30012752)
10. Matsumoto M, Hidakaidaka K, Akiho H, et al. Low stringency hybridization study of the dopamine D4 receptor revealed D4-like mRNA distribution of the orphan seven-transmembrane receptor, APJ, in human brain. Neurosci Lett 1996;219:119-22 (Pubitemid 26396329)
11. Edinger AL, Hoffman TL, Sharron M, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a co-receptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998;72:7934-40 (Pubitemid 28421785)
12. Hosoya M, Kawamata S, Fukusumi R, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000;275:21061-7 (Pubitemid 30481796)
13. O'Carroll AM, Don ALJ, Lolait SJ. APJ receptor mRNA expression in the rat hypothalamic paraventricular nucleus: regulation by stress and glucocorticoids. J Neuroendocrinology 2003;15:1095-101 (Pubitemid 37369171)
14. O'Carroll AM, Lolait SJ. Regulation of rat APJ receptor messenger ribonucleic acid expression in magnocellular neurons of the paraventricular and supraoptic nuclei by osmotic stimuli. J Neuroendocrinology 2003;15:661-6 (Pubitemid 36789965)
15. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Reg Peptides 2004;118:119-25 (Pubitemid 38296725)
16. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Reg Peptides 2005;126:233-40 APJ is localized in cardiomyocytes and vascular tissue.
17. Katugampola SD, MacGuire JJ, Mathewson SR, Davenport AP. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132:1255-60 (Pubitemid 32234709)
18. Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91:434-40 The first report of apelin as inotropic agent.
19. Zhang J, Ren CX, Qi YF, et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci 2006;79:1153-9 (Pubitemid 44128578)
20. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006;41:798-806 (Pubitemid 44635562)
21. Ronkainen V-P, Ronkainen JJ, Hanninen SL, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 2007;21:1821-30 (Pubitemid 46855628)
22. Alturi P, Morine KJ, Liao GP, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 2007;12:127-38 (Pubitemid 46786647)
23. Foldes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308:480-5 The first report that plasma apelin levels are lowered in moderate - severe heart failure.
24. Chen MM, Ashley EA, Deng DXF, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003;108:1432-9 (Pubitemid 37176447)
25. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart. Vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54:598-604 The first report identifying molecular form of apelin in human heart.
26. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 2010;160:1785-95
27. Castan-Laurell I, Boucher J, Dray C, et al. Apelin, a novel adipokine over-produced in obesity: friend or foe? Mol Cell Endocrinol 2005;245:7-9
28. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-71 (Pubitemid 40396885)
29. Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Reg Peptides 2005;130:7-13 (Pubitemid 40966016)
30. Garcia-Diaz D, Campion J, Milagro FI, Martinez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem 2007;305:87-94 (Pubitemid 47517171)
31. Higuchi K, Masaki T, Gotoh K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007;148:2690-7 (Pubitemid 46984786)
32. Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilisation in normal and obese insulin-resistant mice. Cell Metab 2008;8:437-45
33. Jia YX, Lu ZF, Zhang J, et al. Apelin activates L-arginine/nitric oxides synthase/nitric oxide pathways in rat aortas. Peptides 2007;28:2023-9 (Pubitemid 47419100)
34. Zhong JC, Yu XY, Huang Y, et al. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 2007;74:388-95 (Pubitemid 46693698)
35. Hashimoto T, Kihara M, Ishida J, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2006;26:1267-72 (Pubitemid 44305369)
36. Masri B, Morin N, Cornu M, et al. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 2004;18:1909-11
37. Masri B, Morin N, Pedebernade L, et al. The apelin receptor is coupled to gi1 or gi2 protein and is differentially desensitized by apelin fragments J Biol Chem 2006;281:18317-26
38. Kasai A, Shintani N, Oda M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004;325:395-400 (Pubitemid 39458008)
39. Farfasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocytes contractility and electrophysiology. Biochem Biophys Res Commun 2007;357:889-95 (Pubitemid 46711085)
40. Simpkin JC, Yellon DM, Davidson SM, et al. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia reperfusion injury. Basic Res Cardiol 2007;102:518-28 (Pubitemid 47578397)
41. Cheng X, Cheng XS, Pang CCY. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003;470:171-5 (Pubitemid 36694473)
42. Kagiyama S, Fukuhara M, Matsumura K, et al. Central and peripheral cardiovascular actions of apelin in conscious rats. Reg Peptides 2005;125:55-9 (Pubitemid 39593708)
43. Charles CJ, Rademaker MT, Richards AM. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol 2006;189:701-10 The first report of apelin bioactivity in a large conscious mammal model.
44. King AJ, Pfeffer JM, Pfeffer MA, Brenner BM. Systemic hemodynamic effects of endothelin in rats. Am J Physiol 1990;258:H787-92
45. Rohmeiss P, Photiadis J, Rohmeiss S, Unger T. Hemodynamic actions of intravenous endothelin in rats: comparison with sodium nitroprusside and methoxamine. Am J Physiol 1990;258:H337-46
46. Gardiner SM, March JE, Kemp PA, Bennet T. Bolus injection of human urotensin II in conscious rats evoke a biphasic haemodynamic response. Br J Pharmacol 2004;143:422-30 (Pubitemid 39424831)
47. Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005;146:231-6 The first report of a putative APJ receptor antagonist.
48. Graser T, Vanhoute PM. Hypoxic contraction of canine coronary arteries: role of endothelium and cGMP. Am J Physiol 1991;261:H1769-77
49. Rastaldo R, Pagliaro P, Cappello S, et al. Nitric oxide and cardiac function. Life Sci 2007;81:779-93 (Pubitemid 47332516)
50. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscles. Eur J Pharmacol 2006;553:222-8 (Pubitemid 44779594)
51. Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004;110(suppl II):II-187-93
52. Ashley EA, Powers J, Chen M, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005;65:73-82 (Pubitemid 40038480)
53. Reaux A, De Mota N, Skultetyova I, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the brain. J Neurochem 2001;77:1085-96 (Pubitemid 32467063)
54. De Mota N, Reaux-Le Goazigo A, El Messari S, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Nat Acad Sci 2004;101:10464-9 (Pubitemid 38924948)
55. Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002;291:1208-12 (Pubitemid 34694318)
56. Jaszeberenyi M, Bujdoso E, Telegdy G. Behavioural, neuroendocrine and thermoregulatory actions of apelin-13. Neuroscience 2004;129:811-16 (Pubitemid 39487132)
57. Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, et al. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. Am J Physiol 2007;292:E7-15
58. Hus-Citharel A, Bouby N, Frugiere A, et al. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int 2008;74:486-94
59. Kuba K, Zhang L, Imai Y, et al. Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007;101:e32-42
60. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004;279:26274-9 (Pubitemid 38798776)
61. Roberts EM, Newson MJF, Pope GR, et al. Abnormal fluid homeostasis in apelin receptor knockout mice. J Endocrinol 2009;202:453-62
62. Hashimoto T, Kihura M, Imai N, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007;171:1705-12 (Pubitemid 350158330)
63. Charo DN, Ho M, Fajardo G, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol 2009;297:H1904-13
64. Kleinz MJ, Baxter GF. Apelin reduces myocardial reperfusion injury independently of PI3K.Akt and P7036 kinase. Reg Peptides 2008;146:271-7
65. Zeng XJ, Zhang LK, Wang HZ, et al. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009;30:1144-52
66. Jia Y-X, Pan C-S, Zhang J, et al. Apelin protects myocardial injury induced by isoproterenol in rats. Reg Peptides 2006;133:147-54 The first report to suggest apelin may be cardioprotective.
67. Falcao-Pires I, Goncalves N, Henriques-Coelho T, et al. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol 2009;296:H2007-14
68. Foussal C, Lairez O, Calise D, et al. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Letters 2010;584:2363-70
69. Sonmez A, Celebi G, Erdem G, et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertension 2010;32:179-83
70. Ellinor PT, Low AF, MacRae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006;27:222-6 (Pubitemid 43069041)
71. Li Z, Bai Y, Hu J. Reduced apelin levels in stable angina. Internal Medicine 2008;47:1951-5
72. Kadoglou NPE, Lampropoulos S, Kapelouzou A, et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease - KOZANI STUDY. Transl Res 2010;155:238-46
73. Weir RAP, Chong KS, Dalzell JR, et al. Plasma apelin concentration is depressed following myocardial infarction in man. Eur J Heart Fail 2009;11:551-8
74. Goetze JP, Rehfeld JF, Carlsen J, et al. Apelin: a new plasma marker of cardiopulmonary disease. Reg Peptides 2006;133:134-8 (Pubitemid 41820346)
75. Chong KS, Gardiner RS, Morton JJ, et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006;8:355-60 The largest cohort (200) tested showing plasma apelin levels are reduced in heart failure.
76. Francia P, Salvati A, Balla C, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 2007;9:306-9 Plasma apelin levels which are reduced in heart failure can be restored by successful CRT treatment.
77. Gao LR, Xu RY, Zhang NK, et al. Increased apelin following bone marrow mononuclear cell transplantation contributes to the improvement of cardia function in patients with severe heart failure. Cell Transplant 2009;18:1311-18
78. Van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3 and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24 A negative study in a large cohort showing apelin does not have prognostic utility in heart failure.
79. Chandrasekaran B, Kalra PR, Donovan J, et al. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Cardiac Fail 2010;16:556-61 The first report identifying human heart as a likely source of circulating apelin.
80. Mesmin C, Dubois M, Becher F, et al. Liquid chromatography/tandem mass spectrometry assay for the absolute quantification of the expected circulating apelin peptides in human plasma. Rapid Commun Mass Spectrom 2010;24:2875-84 A detailed analysis (mass spectrometry) of molecular forms of circulating apelin in humans.
81. Japp AG, Cruden NL, Amer DAB, et al. Vascular effects of apelin in man. J Am Coll Cardiol 2008;52:908-13 The first report of apelin administered to humans showing vasodilation.
82. Japp AG, Cruden NL, Barnes G, et al. Acute cardiovascular effects of apelin in humans. Potential role in patients with chronic heart failure. Circulation 2010;121:1818-27 The first report of apelin administered to HF patients.
83. Zhong JC, Huang Y, Yung LM, et al. The novel peptide apelin regulates intrarenal artery tone in diabetic mice. Reg Peptides 2007;144:109-14 (Pubitemid 350030306)
84. Gurzu B, Petrescu BC, Costuleanu M, et al. Interactions between apelin and angiotensin II on rat portal vein. JRAAS 2006;7:212-16 (Pubitemid 46380771)
85. Fan X, Zhou N, Zhang X, et al. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemisty 2003;42:10163-8 (Pubitemid 37052035)
86. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003;84:1162-72 (Pubitemid 36330668)
87. Pitkin SL, Maguire JJ, Bonner TI, Davenport AJ. International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 2010;62:331-42
88. Hamada J, Kimura J, Ishida J, et al. Evaluation of novel cyclic analogues of apelin. Int J Molecular Med 2008;22:547-52
89. Iturrioz X, Alvear-Perez R, De Mota N, et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 2010;24:1506-17